Puretech Health’s (PRTC) “Buy” Rating Reiterated at Liberum Capital
A number of other research analysts also recently commented on the stock. Peel Hunt reaffirmed a buy rating and set a GBX 302 ($4.17) price objective on shares of Puretech Health in a research note on Tuesday, December 19th. Numis Securities reaffirmed a buy rating and set a GBX 259 ($3.58) price objective on shares of Puretech Health in a research note on Tuesday, February 20th. N+1 Singer reaffirmed a buy rating on shares of Puretech Health in a research note on Thursday, November 30th. Finally, Jefferies Group reaffirmed a buy rating on shares of Puretech Health in a research note on Friday, November 17th. Five investment analysts have rated the stock with a buy rating, Puretech Health has an average rating of Buy and a consensus target price of GBX 260.20 ($3.59).
Puretech Health (LON:PRTC) opened at GBX 170 ($2.35) on Thursday. Puretech Health has a one year low of GBX 110 ($1.52) and a one year high of GBX 183.50 ($2.54). The company has a market cap of $413.90 and a PE ratio of -894.74.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/03/04/puretech-healths-prtc-buy-rating-reiterated-at-liberum-capital.html.
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.